Cargando…
SCLC extensive disease – treatment guidance by extent or/and biology of response?
In extensive disease of small cell lung cancer a doubling of the one-year-survival rate was reported in August 2007 by prophylactic cranial irradiation applied to patients who experienced any response to initial chemotherapy. We discuss the treatment concept of extensive disease in the face of the l...
Autores principales: | Eckert, Franziska, Müller, Arndt-Christian |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2570671/ https://www.ncbi.nlm.nih.gov/pubmed/18831728 http://dx.doi.org/10.1186/1748-717X-3-33 |
Ejemplares similares
-
Is transformed small cell lung cancer (SCLC) different from de novo SCLC?
por: Park, Cheol-Kyu, et al.
Publicado: (2019) -
Durvalumab: A Review in Extensive-Stage SCLC
por: Al-Salama, Zaina T.
Publicado: (2021) -
Correction to: Durvalumab: A Review in Extensive-Stage SCLC
por: Al-Salama, Zaina T.
Publicado: (2021) -
Racial and Other Healthcare Disparities in Patients With Extensive-Stage SCLC
por: Tapan, Umit, et al.
Publicado: (2020) -
Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)
por: Saltos, Andreas, et al.
Publicado: (2020)